These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 37812385)
1. Lysine-Specific Demethylase 1 (LSD1) Inhibitors: Peptides as an Emerging Class of Therapeutics. Baby S; Shinde SD; Kulkarni N; Sahu B ACS Chem Biol; 2023 Oct; 18(10):2144-2155. PubMed ID: 37812385 [TBL] [Abstract][Full Text] [Related]
2. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment. Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714 [TBL] [Abstract][Full Text] [Related]
3. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials. Noce B; Di Bello E; Fioravanti R; Mai A Front Pharmacol; 2023; 14():1120911. PubMed ID: 36817147 [TBL] [Abstract][Full Text] [Related]
4. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective. Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269 [TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures. Ota Y; Kakizawa T; Itoh Y; Suzuki T Molecules; 2018 May; 23(5):. PubMed ID: 29734782 [TBL] [Abstract][Full Text] [Related]
12. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy. Shen L; Wang B; Wang SP; Ji SK; Fu MJ; Wang SW; Hou WQ; Dai XJ; Liu HM J Med Chem; 2024 Jan; 67(2):922-951. PubMed ID: 38214982 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment. Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602 [TBL] [Abstract][Full Text] [Related]
14. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860 [TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. Culhane JC; Wang D; Yen PM; Cole PA J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560 [TBL] [Abstract][Full Text] [Related]
17. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors. Kakizawa T; Ota Y; Itoh Y; Suzuki T Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865 [TBL] [Abstract][Full Text] [Related]
18. Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes. El Mansouri FE; Nebbaki SS; Kapoor M; Afif H; Martel-Pelletier J; Pelletier JP; Benderdour M; Fahmi H Arthritis Res Ther; 2014 May; 16(3):R113. PubMed ID: 24886859 [TBL] [Abstract][Full Text] [Related]
19. A Structure-Activity Relationship Study of SNAIL1 Peptides as Inhibitors of Lysine-Specific Demethylase 1. Takada Y; Adachi K; Fujinaga Y; Yamashita Y; Itoh Y; Suzuki T Chem Pharm Bull (Tokyo); 2024; 72(2):155-160. PubMed ID: 38296557 [TBL] [Abstract][Full Text] [Related]